Curated News
By: NewsRamp Editorial Staff
April 13, 2026
LIXTE's LB-100 Shows 40% Disease Control in Ovarian Cancer Trial
TLDR
- LIXTE Biotechnology's LB-100 combination shows a 40% disease control rate in ovarian cancer trials, potentially giving investors an edge in the immunotherapy market.
- LIXTE's LB-100 compound, a PP2A inhibitor, combines with dostarlimab in clinical trials, achieving a 40% disease control rate with acceptable safety in 20 ovarian cancer patients.
- This cancer treatment advancement offers hope for improved survival and better quality of life for patients with ovarian clear cell carcinoma.
- LIXTE's novel approach activates lethality in cancer cells, pioneering a new treatment paradigm that could transform how we fight this disease.
Impact - Why it Matters
This news matters because it highlights a potential breakthrough in treating ovarian clear cell carcinoma, a challenging cancer subtype with limited effective therapies. The 40% disease control rate and encouraging survival trends suggest that LB-100 in combination with dostarlimab could enhance immunotherapy responses, offering new hope for patients who often face poor prognoses. As cancer remains a leading cause of death globally, advancements like this from LIXTE's activation lethality approach could pave the way for more effective, targeted treatments, potentially improving survival rates and quality of life. For investors and the medical community, it signals progress in a high-need area of oncology, with implications for future clinical applications and market opportunities.
Summary
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, has unveiled promising preliminary results from its clinical trial evaluating the proprietary compound LB-100 in combination with dostarlimab for ovarian clear cell carcinoma. Presented at the 2026 Society of Gynecologic Oncology conference in San Juan, Puerto Rico, interim data from 20 evaluable patients revealed a 40% disease control rate and encouraging survival trends, with an acceptable safety profile. This supports continued enrollment in an expanded cohort as the company investigates the combination's potential to enhance immunotherapy response, marking a significant step in advancing cancer treatments through its novel approach.
LIXTE's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on preclinical data, it holds promise to significantly enhance chemotherapies and immunotherapies, improving outcomes for patients with cancer. The company's pioneering effort in the field of activation lethality represents a new treatment paradigm, supported by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma, with additional information available at www.lixte.com.
Through its wholly owned subsidiary, Liora Technologies Europe Ltd., LIXTE is also developing electronically controlled proton therapy systems, such as the LiGHT System, which offers advantages over current technologies for treating tumors. This news was distributed via BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides enhanced press release distribution and corporate communications solutions. For more details, the full press release can be accessed at https://ibn.fm/alcex, and updates on LIXT are available in the company's newsroom at https:/ibn.fm/LIXT, highlighting the ongoing advancements in biotechnology and life sciences.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, LIXTE's LB-100 Shows 40% Disease Control in Ovarian Cancer Trial
